Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Zanaboni

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Seminars in Oncology|February 1, 1994
High-dose intensity regimens with epirubicin in ovarian cancerJ B Vermorken, G Bolis, R E van Rijswijk, et al.
European Journal of Gynaecological Oncology|January 1, 1995
High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experienceJ B Vermorken, A Kobierska, M E van der Burg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancerG Bolis, G Favalli, S Danese, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2009
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumoursA Perotti, C Sessa, A Mancuso, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2003
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923)R E N van Rijswijk, J B Vermorken, N Reed, et al.
European Journal of Gynaecological Oncology|August 15, 2001
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of CancerH C Wagenaar, S Pecorelli, I Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2003
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer GroupF H van Wijk, M S Aapro, G Bolis, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Seminars in Oncology|February 1, 1994
High-dose intensity regimens with epirubicin in ovarian cancerJ B Vermorken, G Bolis, R E van Rijswijk, et al.
European Journal of Gynaecological Oncology|January 1, 1995
High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experienceJ B Vermorken, A Kobierska, M E van der Burg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancerG Bolis, G Favalli, S Danese, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2009
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumoursA Perotti, C Sessa, A Mancuso, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2003
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923)R E N van Rijswijk, J B Vermorken, N Reed, et al.
European Journal of Gynaecological Oncology|August 15, 2001
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of CancerH C Wagenaar, S Pecorelli, I Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2003
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer GroupF H van Wijk, M S Aapro, G Bolis, et al.
Pageof 5